help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frystyk, J.
Right arrow Articles by Ørskov, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frystyk, J.
Right arrow Articles by Ørskov, H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*GLUCOSE
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 9 3124-3127
Copyright © 1997 by The Endocrine Society


Original Studies

The Effect of Oral Glucose on Serum Free Insulin-Like Growth Factor-I and -II in Healthy Adults1

Jan Frystyk, Thorbjørn Grøfte, Christian Skjærbæk and Hans Ørskov

Institute of Experimental Clinical Research, Medical Research Laboratories, Aarhus University Hospital, Denmark

Address correspondence and requests for reprints to: Jan Frystyk, MD, PhD, Institute of Experimental Clinical Research, Aarhus Kommune Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark.

Insulin-like growth factor (IGF) binding protein-I (IGFBP-1) has been suggested to regulate the availability of free IGF and the glucose lowering activity of the IGF-system in relation to fuel supply. Our recent observations of significant inverse correlations between free IGF-I and IGFBP-1 in cross-sectionally collected fasting serum samples support a possible physiological association between the peptides. To further study the impact of IGFBP-1 on free IGF levels and the possible participation of the IGF-system in glucose homeostasis, we studied the time course of changes in IGFBP-1 and free IGFs in 13 healthy subjects undergoing an oral glucose tolerance test (OGTT). Serum was collected every 30 min for 330 min.

Glucose, insulin, and GH followed the expected patterns and had regained baseline levels at 270 min. Total IGF-I and free and total IGF-II remained unaltered. IGFBP-1 decreased significantly by 37–52% (P < 0.05) from 150 to 210 min, whereafter the concentration gradually increased by 75% to a level that tended to be above baseline (P = 0.052). Free IGF-I decreased by 29–38% (P < 0.05) at the end of the study (270–330 min). IGFBP-1 was inversely correlated to free IGF-I at baseline (r = -0.57; P < 0.05), as well as during the OGTT (r = 0.66; P < 0.0001). In contrast, free IGF-II was not correlated to IGFBP-1. Insulin, but not free IGF-I, correlated significantly with serum glucose (P < 0.05).

These results extend our previous findings of an inverse correlation between free IGF-I and IGFBP-1 in cross-sectional studies to include longitudinal observations, and thus further substantiates the hypothesis that IGFBP-1 is an important determinant of free IGF-I in vivo. Significant changes in free IGF-I were observed only in the late postprandial phase, when glucose and insulin were fully normalized, demonstrating that free IGFs probably do not participate in glucoregulation to any significant degree during an oral glucose load in healthy subjects.




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
J.-W. Chen, M. F Nielsen, A. Caumo, H. Vilstrup, J. S. Christiansen, and J. Frystyk
Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis.
Eur. J. Endocrinol., August 1, 2006; 155(2): 285 - 292.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
E. K. Wei, J. Ma, M. N. Pollak, N. Rifai, C. S. Fuchs, S. E. Hankinson, and E. Giovannucci
C-Peptide, Insulin-like Growth Factor Binding Protein-1, Glycosylated Hemoglobin, and the Risk of Distal Colorectal Adenoma in Women.
Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 750 - 755.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
E. K. Wei, J. Ma, M. N. Pollak, N. Rifai, C. S. Fuchs, S. E. Hankinson, and E. Giovannucci
A Prospective Study of C-Peptide, Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-1, and the Risk of Colorectal Cancer in Women
Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 850 - 855.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
V. Cingel-Ristic, B. F. Schrijvers, A. K. van Vliet, R. Rasch, V. K. M. Han, S. L. S. Drop, and A. Flyvbjerg
Kidney Growth in Normal and Diabetic Mice Is Not Affected by Human Insulin-Like Growth Factor Binding Protein-1 Administration
Experimental Biology and Medicine, February 1, 2005; 230(2): 135 - 143.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
M Shimizu, J T Dickey, H Fukada, and W W Dickhoff
Salmon serum 22 kDa insulin-like growth factor-binding protein (IGFBP) is IGFBP-1
J. Endocrinol., January 1, 2005; 184(1): 267 - 276.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
V. Cingel-Ristic, J. W. van Neck, J. Frystyk, S. L. S. Drop, and A. Flyvbjerg
Administration of Human Insulin-Like Growth Factor-Binding Protein-1 Increases Circulating Levels of Growth Hormone in Mice
Endocrinology, September 1, 2004; 145(9): 4401 - 4407.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
A. NANDI, Y. KITAMURA, C. R. KAHN, and D. ACCILI
Mouse Models of Insulin Resistance
Physiol Rev, April 1, 2004; 84(2): 623 - 647.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Norrelund, J. Frystyk, J. O. L. Jorgensen, N. Moller, J. S. Christiansen, H. Orskov, and A. Flyvbjerg
The Effect of Growth Hormone on the Insulin-Like Growth Factor System during Fasting
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3292 - 3298.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
R. A. Krajcik, N. D. Borofsky, S. Massardo, and N. Orentreich
Insulin-like Growth Factor I (IGF-I), IGF-binding Proteins, and Breast Cancer
Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1566 - 1573.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. Mesotten, P. J. D. Delhanty, F. Vanderhoydonc, K. V. Hardman, F. Weekers, R. C. Baxter, and G. van den Berghe
Regulation of Insulin-Like Growth Factor Binding Protein-1 during Protracted Critical Illness
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5516 - 5523.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
M. S. Sandhu, D. B. Dunger, and E. L. Giovannucci
Insulin, Insulin-Like Growth Factor-I (IGF-I), IGF Binding Proteins, Their Biologic Interactions, and Colorectal Cancer
J Natl Cancer Inst, July 3, 2002; 94(13): 972 - 980.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. E. L. Katz, D. D. DeLeon, H. Zhao, and A. F. Jawad
Free and Total Insulin-Like Growth Factor (IGF)-I Levels Decline during Fasting: Relationships with Insulin and IGF-Binding Protein-1
J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2978 - 2983.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Frystyk, K. Hojlund, K. N. Rasmussen, S. P. Jorgensen, M. Wildner-Christensen, and H. Orskov
Development and Clinical Evaluation of a Novel Immunoassay for the Binary Complex of IGF-I and IGF-Binding Protein-1 in Human Serum
J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 260 - 266.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Sevette, A. J. Kee, A. R. Carlsson, R. C. Baxter, and R. C. Smith
Parenteral nutrition with lipid or glucose suppresses liver growth and response to GH in adolescent male rats
Am J Physiol Endocrinol Metab, November 1, 2001; 281(5): E1063 - E1072.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
J. K. Cruickshank, A. H. Heald, S. Anderson, J. E. Cade, J. Sampayo, L. K. Riste, A. Greenhalgh, W. Taylor, W. Fraser, A. White, et al.
Epidemiology of the Insulin-like Growth Factor System in Three Ethnic Groups
Am. J. Epidemiol., September 15, 2001; 154(6): 504 - 513.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. C. Baxter
Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities
Am J Physiol Endocrinol Metab, June 1, 2000; 278(6): E967 - E976.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. Frystyk, P. J. D. Delhanty, C. Skjarbak, and R. C. Baxter
Changes in the circulating IGF system during short-term fasting and refeeding in rats
Am J Physiol Endocrinol Metab, August 1, 1999; 277(2): E245 - E252.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. Frystyk, H. Gronbak, C. Skjarbak, A. Flyvbjerg, H. Orskov, and R. C. Baxter
Developmental Changes in Serum Levels of Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 and -3, and the Acid-Labile Subunit in Rats
Endocrinology, October 1, 1998; 139(10): 4286 - 4292.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society